10x Genomics

Pleasanton, California, USA

1,518 Total Employees

Year Founded: 2012

View Website

10x Genomics Company Stability & Growth

Updated on February 07, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for 10x Genomics?

Strengths in category leadership, IP position, and active platform expansion are accompanied by flat underlying revenue, instrument softness, pricing pressure from lower‑cost alternatives, and continued losses. Together, these dynamics suggest a resilient but tested leader whose near‑term stability hinges on consumables pull‑through, competitive responses to new entrants, and an eventual recovery in instrument demand and research funding.

Positive Themes About 10x Genomics

Strong Market Position & Advantage: 10x is widely regarded as the leader in single‑cell and a co‑leader in spatial biology, with Chromium, Visium and Xenium as reference platforms in many labs. Legal wins and injunctions in spatial further reinforce competitive positioning.
Product Line Growth: Ongoing chemistry and platform updates (GEM‑X, Visium HD, Xenium Protein/RNA multiomics) and launches like next‑gen Chromium Flex indicate continued expansion of content and capabilities. The planned acquisition of Scale Biosciences aims to broaden single‑cell workflows and support medium‑term growth.
Investor Backing & Capital Strength: The company maintains a sizable cash and securities balance alongside a large recurring consumables base. Management is prioritizing cash and costs while guiding quarter‑to‑quarter to navigate a softer funding environment.

Considerations About 10x Genomics

Stagnant Revenue: Core revenue was flat to slightly down in 2025 excluding one‑time items, following a modest decline in 2024. Instrument sales declined materially, weighing on overall growth despite consumables strength.
Weak Market Position & Pricing Challenges: Pricing headwinds and lower‑priced, instrument‑light alternatives are gaining traction. Illumina’s entry via the Fluent BioSciences acquisition increases pressure in single‑cell prep kits.
Declining Profitability: The company remains unprofitable with ongoing losses despite operating discipline improvements. Gross margin pressure and funding uncertainty have delayed a clean return to profitability.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.

View All 20 Jobs at 10x Genomics

Is This Your Company? Claim Profile